← Eichor
Study identifier: NCT05203965 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

Condition: Familial Alcoholism Vulnerability  ·  Sponsor: Yale University

PhaseEARLY_Phase 1
Planned participants80
Who can joinAll sexes, 18 Years to 45 Years
Healthy volunteersYes

About this study

The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.

This description comes directly from the study's public registry record.

Talk to the study team

Godfrey D Pearlson, MD  ·  203-737-3416  ·  godfrey.pearlson@hhchealth.org

Always discuss trial participation with your own doctor first.

Locations (1)

Hartford HospitalHartford, Connecticut, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05203965